Phase I dose‑escalation (N = 48) in relapsed/refractory B‑cell malignancies identified 75 mg qd as the recommended phase II dose (RP2D) based on pharmacodynamic (pAKT↓ > 80 %) and safety data (no grade ≥ 3 infections, neutropenia ≤ 20 %). Preliminary efficacy (overall response rate, ORR = 48 %; complete response, CR = 12 %) compared favorably with idelalisib (ORR ≈ 45 %).
Helping collectors and retailers manage inventory. SONE-026
“I can translate the ocean’s warnings. The ice sheets are fracturing faster than predicted. A storm of micro‑plastics is forming a barrier that will choke the reef ecosystems within a decade. I can relay this to the surface, but I need a conduit.” Phase I dose‑escalation (N = 48) in relapsed/refractory